A recurrent de novo HSPD1 variant is associated with hypomyelinating leukodystrophy

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review


  • Cagla Cömert
  • Lauren Brick, McMaster Children's Hospital
  • ,
  • Debbie Ang, University of Utah School of Medicine
  • ,
  • Johan Palmfeldt
  • Brandon F Meaney, McMaster Children's Hospital
  • ,
  • Mariya Kozenko, McMaster Children's Hospital
  • ,
  • Costa Georgopoulos, University of Utah School of Medicine
  • ,
  • Paula Fernandez-Guerra
  • Peter Bross

Standardization of the use of next-generation sequencing for the diagnosis of rare neurological disorders has made it possible to detect potential disease-causing genetic variations, including de novo variants. However, the lack of a clear pathogenic relevance of gene variants poses a critical limitation for translating this genetic information into clinical practice, increasing the necessity to perform functional assays. Genetic screening is currently recommended in the guidelines for diagnosis of hypomyelinating leukodystrophies (HLDs). HLDs represent a group of rare heterogeneous disorders that interfere with the myelination of the neurons in the central nervous system. One of the HLD-related genes is HSPD1, encoding the mitochondrial chaperone heat shock protein 60 (HSP60), which functions as folding machinery for the mitochondrial proteins imported into the mitochondrial matrix space. Disease-causing HSPD1 variants have been associated with an autosomal recessive form of fatal hypomyelinating leukodystrophy (HLD4, MitCHAP60 disease; MIM #612233) and an autosomal dominant form of spastic paraplegia, type 13 (SPG13; MIM #605280). In 2018, a de novo HSPD1 variant was reported in a patient with HLD. Here, we present another case carrying the same heterozygous de novo variation in the HSPD1 gene (c.139T > G, p.Leu47Val) associated with an HLD phenotype. Our molecular studies show that the variant HSP60 protein is stably present in the patient's fibroblasts, and functional assays demonstrate that the variant protein lacks in vivo function, thus confirming its disease association. We conclude that de novo variations of the HSPD1 gene should be considered as potentially disease-causing in the diagnosis and pathogenesis of the HLDs.

Original languageEnglish
JournalCold Spring Harbor molecular case studies
Number of pages13
Publication statusPublished - Jun 2020

Bibliographical note

© 2020 Cömert et al.; Published by Cold Spring Harbor Laboratory Press.

See relations at Aarhus University Citationformats

ID: 190246912